id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-323333-keshu99t	Schleis, Thomas G.	The Process: New Methods of Purification and Viral Safety	2013-01-16		.txt	text/plain	2212	132	47	From the transmission of hepatitis C virus by gammaglobulins in 1994 to the emergence of new viruses and concern over prions, intravenous immunoglobulin (IGIV) manufacturers have continued to address safety issues and respond to changing needs. Because the different techniques can affect the biologic function of the IgG molecule, the methods of viral inactivation may account for some of the differences among IGIV products in terms of side effects and efficacy (Table 1) . Because intravenous immunoglobulins are derived from human plasma, they are potentially susceptible to contamination by a variety of blood-borne pathogens; consequently, patients receiving and clinicians administering IGIV are concerned about disease transmission. From the transmission of HCV by gammaglobulins in 1994 to the emergence of new viruses or concern over prions, IGIV manufacturers have continued to address safety issues and respond to changing needs.	./cache/cord-323333-keshu99t.txt	./txt/cord-323333-keshu99t.txt